Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Dual-specificity fusion toxin selective and potent agent for AML treatment
December 14th, 2004
A dual-specificity fusion toxin, DTU2GMCSF, may be a selective and potent agent for the treatment of aculte myeloid leukemia. According to a study from the United States, "Novel agents to treat acute myeloid leukemia (AML) are needed with increased efficacy and specificity. "We have synthesized a dual-specificity fusion toxin DTU2GMCSF composed of the catalytic and translocation domains of diphtheria toxin (DT) fused to the granulocyte-macrophage colony-stimulating factor (GM-CSF) in which the DT furin cleavage site 163RVRRSV170 is modified to a urokinase plasminogen activator (uPA) cleavage site (163)GSGRSA(170), termed U2." ...
Source: Cancer Weekly (2004-12-14)
|
